TrialLancet (London, England)2013

Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study.

W David Strain et al.PubMed ↗Publisher ↗

No numbers read from the abstract.